多瑞医药：筹划控制权变更事项，公司股票9月29日起停牌

Group 1 - The core point of the article is that Duori Pharmaceutical is undergoing a potential change in control, which may affect its major shareholder and actual controller [1] - Duori Pharmaceutical's stock will be suspended from trading starting September 29, 2025, for a period not exceeding two trading days to ensure fair information disclosure and avoid abnormal stock price fluctuations [1] - As of the report, Duori Pharmaceutical has a market capitalization of 3.2 billion yuan [1] Group 2 - For the fiscal year 2024, Duori Pharmaceutical's revenue composition is 57.85% from the pharmaceutical manufacturing industry and 42.15% from other sources [1]